Fast Five Quiz: Precision Medicine in Cancer

Winston W. Tan, MD

July 15, 2021

The evolution of the treatment landscape for NSCLC marks a shift in precision medicine. Historically, platinum-based doublets were chosen for every patient. Now during diagnosis, all patients with metastatic NSCLC should undergo molecular testing measuring EGFR, ALK, ROS1, PD-L1, NRTK, BRAF, and KRAS codon 12 to help determine whether a tyrosine kinase inhibitor (TKI) should be used in place of cytotoxic chemotherapy.

Although pathways of oncogenic addiction have been characterized the most in lung cancer, researchers have also made strides in providing personalized medicine in the areas of colorectal cancer, breast cancer, leukemia, lymphoma, melanoma, esophageal cancer, stomach cancer, ovarian cancer, and thyroid cancer.

Learn more about genetic testing to select targeted therapies for patients with NSCLC.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Winston W. Tan. Fast Five Quiz: Precision Medicine in Cancer - Medscape - Jul 15, 2021.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

Return to Article

Post as: